Kyowa Kirin has announced the global discontinuation of all ongoing clinical trials for rocatinlimab, an anti-OX40 monoclonal ...
Two of Intellia Therapeutics' Phase III gene therapy trials were put on clinical hold by the FDA in October 2025.
Faron Pharmaceuticals and City of Hope are to co-develop a Phase II for evaluating bexmarilimab in patients with r/r MDS.
Opus Genetics has reported early findings from its ongoing Phase I/II clinical trial of the OPGx-BEST1 gene therapy to treat ...
Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...
MSD has announced findings from the pivotal Phase III LITESPARK-022 trial, assessing the Keytruda-Welireg combination as adjuvant therapy for patients with clear cell RCC after nephrectomy.
Mahzi Therapeutics has dosed the first patient in its Phase I/II UNITE study assessing MZ-1866, an investigational gene ...
The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...
Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.
In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...
Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...
C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results